Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy

被引：14
作者：
Korte, W
Jost, C
Cogliatti, S
Hess, U
Cerny, T [1 ]
机构：
[1] Kantonsspital, Div Med Oncol, CH-9007 St Gallen, Switzerland
[2] Kantonsspital, Inst Clin Chem & Haematol, CH-9007 St Gallen, Switzerland
[3] Kantonsspital, Inst Pathol, CH-9007 St Gallen, Switzerland
来源：
ANNALS OF ONCOLOGY | 1999年 / 10卷 / 10期
关键词：
CD20; IL-6; monitoring; multiple myeloma;
D O I：
10.1023/A:1008310819049
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1249 / 1250
页数：2
相关论文
共 50 条
[31]   A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from [J].
Ding, Hanyi ;
Zhang, Xiaoyuan ;
Gang, Dongxu ;
He, Xiaoyu ;
Jiang, Songfu .
TRANSLATIONAL CANCER RESEARCH, 2022, 11 (04) :772-783
[32]   CD38: targeted therapy in multiple myeloma and therapeutic potential for solid cancers [J].
Jiao, Ying ;
Yi, Ming ;
Xu, Linping ;
Chu, Qian ;
Yan, Yongxiang ;
Luo, Suxia ;
Wu, Kongming .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (11) :1295-1308
[33]   Resistance Mechanisms towards CD38-Directed Antibody Therapy in Multiple Myeloma [J].
Franssen, Laurens E. ;
Stege, Claudia A. M. ;
Zweegman, Sonja ;
van de Donk, Niels W. C. J. ;
Nijhof, Inger S. .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (04)
[34]   Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma [J].
Aref, Salah ;
Azmy, Emaad ;
El-Gilany, Abdel Hady .
HEMATOLOGICAL ONCOLOGY, 2017, 35 (01) :51-57
[35]   Plasmacytoma relapses in the absence of systemic progression post-high-dose therapy for multiple myeloma [J].
Terpos, E ;
Rezvani, K ;
Basu, S ;
Milne, AE ;
Rose, PE ;
Scott, GL ;
Rahemtulla, A ;
Samson, D ;
Apperley, JF .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2005, 75 (05) :376-383
[36]   Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study [J].
Kumar, S. K. ;
Lee, J. H. ;
Lahuerta, J. J. ;
Morgan, G. ;
Richardson, P. G. ;
Crowley, J. ;
Haessler, J. ;
Feather, J. ;
Hoering, A. ;
Moreau, P. ;
LeLeu, X. ;
Hulin, C. ;
Klein, S. K. ;
Sonneveld, P. ;
Siegel, D. ;
Blade, J. ;
Goldschmidt, H. ;
Jagannath, S. ;
Miguel, J. S. ;
Orlowski, R. ;
Palumbo, A. ;
Sezer, O. ;
Rajkumar, S. V. ;
Durie, B. G. M. .
LEUKEMIA, 2012, 26 (01) :149-157
[37]   Anti-Galectin-3 Therapy: A New Chance for Multiple Myeloma and Ovarian Cancer? [J].
Mirandola, Leonardo ;
Nguyen, Diane D. ;
Rahman, Rakhshanda L. ;
Grizzi, Fabio ;
Yu Yuefei ;
Figueroa, Jose A. ;
Jenkins, Marjorie R. ;
Cobos, Everardo ;
Chiriva-Internati, Maurizio .
INTERNATIONAL REVIEWS OF IMMUNOLOGY, 2014, 33 (05) :417-427
[38]   Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance [J].
De Novellis, Danilo ;
Fontana, Raffaele ;
Giudice, Valentina ;
Serio, Bianca ;
Selleri, Carmine .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (01)
[39]   Seed targeting with tiny anti-miR-155 inhibits malignant progression of multiple myeloma cells [J].
Feng, Maoxiao ;
Luo, Xiaochuang ;
Gu, Chunming ;
Fei, Jia .
JOURNAL OF DRUG TARGETING, 2015, 23 (01) :59-66
[40]   Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study [J].
S K Kumar ;
J H Lee ;
J J Lahuerta ;
G Morgan ;
P G Richardson ;
J Crowley ;
J Haessler ;
J Feather ;
A Hoering ;
P Moreau ;
X LeLeu ;
C Hulin ;
S K Klein ;
P Sonneveld ;
D Siegel ;
J Bladé ;
H Goldschmidt ;
S Jagannath ;
J S Miguel ;
R Orlowski ;
A Palumbo ;
O Sezer ;
S V Rajkumar ;
B G M Durie .
Leukemia, 2012, 26 :149-157
12345